ALBO
Income statement / Annual
Last year (2021), Albireo Pharma, Inc.'s total revenue was $40.58 M,
an increase of 388.43% from the previous year.
In 2021, Albireo Pharma, Inc.'s net income was -$151.35 M.
See Albireo Pharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
09/30/2015 |
09/30/2014 |
09/30/2013 |
09/30/2012 |
| Operating Revenue |
$40.58 M |
$8.31 M |
$9.64 M |
$12.74 M |
$1.00 K |
$11.36 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$1.36 M
|
$0.00
|
$2.21 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$39.22 M
|
$8.31 M
|
$7.43 M
|
$12.74 M
|
$1.00 K
|
$11.36 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.97
|
1
|
0.77
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$82.52 M
|
$76.78 M
|
$45.58 M
|
$31.73 M
|
$12.99 M
|
$8.08 M
|
$13.37 M
|
$14.19 M
|
$14.30 M
|
$12.57 M
|
| General & Administrative Expenses |
$0.00
|
$42.45 M
|
$22.96 M
|
$18.06 M
|
$15.25 M
|
$15.79 M
|
$6.40 M
|
$5.60 M
|
$6.84 M
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$69.57 M
|
$42.45 M
|
$22.96 M
|
$18.06 M
|
$15.25 M
|
$15.79 M
|
$6.40 M
|
$5.60 M
|
$6.84 M
|
$6.82 M
|
| Other Expenses |
$10.62 M
|
-$14.65 M
|
$2.21 M
|
$837.00 K
|
-$3.66 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$162.71 M
|
$104.58 M
|
$70.75 M
|
$50.63 M
|
$24.58 M
|
$23.66 M
|
$19.77 M
|
$19.26 M
|
$20.59 M
|
$19.30 M
|
| Cost And Expenses |
$164.06 M
|
$104.58 M
|
$70.75 M
|
$50.63 M
|
$24.58 M
|
$23.66 M
|
$19.77 M
|
$19.26 M
|
$20.59 M
|
$19.30 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$52.00 K
|
$49.00 K
|
$56.00 K
|
$80.00 K
|
| Interest Expense |
$13.93 M
|
$11.36 M
|
$5.30 M
|
$0.00
|
$40.00 K
|
$1.32 M
|
$52.00 K
|
$49.00 K
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$274.00 K
|
$192.00 K
|
$127.00 K
|
$45.00 K
|
$35.00 K
|
$14.00 K
|
$197.00 K
|
$603.00 K
|
$641.00 K
|
$725.00 K
|
| EBITDA |
-$19.82 M |
-$96.08 M |
-$57.29 M |
-$37.85 M |
-$24.13 M |
-$14.96 M |
-$20.58 M |
-$23.77 M |
-$19.90 M |
-$21.51 M |
| EBITDA Ratio |
-0.49
|
-11.56
|
-5.95
|
-2.97
|
-24127
|
-1.32
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-3.04
|
-11.59
|
-6.34
|
-2.97
|
-24577
|
-1.08
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$89.46 M
|
-$11.36 M
|
-$1.61 M
|
-$8.20 M
|
$375.00 K
|
-$3.99 M
|
$2.07 M
|
$10.26 M
|
$1.22 M
|
-$1.43 M
|
| Income Before Tax |
-$34.03 M
|
-$107.63 M
|
-$62.72 M
|
-$46.09 M
|
-$24.20 M
|
-$16.29 M
|
-$18.71 M
|
-$14.11 M
|
-$19.32 M
|
-$20.73 M
|
| Income Before Tax Ratio |
-0.84
|
-12.96
|
-6.51
|
-3.62
|
-24202
|
-1.43
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$117.32 M
|
$11.36 M
|
$8.99 M
|
$20.00 K
|
$212.00 K
|
$62.00 K
|
$29.00 K
|
$26.00 K
|
$15.00 K
|
$18.00 K
|
| Net Income |
-$151.35 M
|
-$119.00 M
|
-$71.70 M
|
-$46.11 M
|
-$24.41 M
|
-$16.35 M
|
-$18.74 M
|
-$14.13 M
|
-$19.34 M
|
-$20.75 M
|
| Net Income Ratio |
-3.73
|
-14.32
|
-7.44
|
-3.62
|
-24414
|
-1.44
|
0
|
0
|
0
|
0
|
| EPS |
-7.87 |
-7.45 |
-5.77 |
-3.94 |
-3.12 |
-13.19 |
-13.7 |
-19.81 |
-37.06 |
-57.19 |
| EPS Diluted |
-7.87 |
-7.45 |
-5.77 |
-3.94 |
-3.12 |
-13.19 |
-13.7 |
-19.8 |
-37.2 |
-57.3 |
| Weighted Average Shares Out |
$19.22 M
|
$15.98 M
|
$12.44 M
|
$11.70 M
|
$7.82 M
|
$1.24 M
|
$1.37 M
|
$713.47 K
|
$521.68 K
|
$362.75 K
|
| Weighted Average Shares Out Diluted |
$19.22 M
|
$15.98 M
|
$12.44 M
|
$11.70 M
|
$7.82 M
|
$1.24 M
|
$1.37 M
|
$713.47 K
|
$521.68 K
|
$362.75 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
